Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanomedicine strategies against multidrug-resistant Acinetobacter baumannii: Delivery, biofilm disruption, and translational considerations.

Nanomedicine : nanotechnology, biology, and medicine·2026
Same author

Ras signalling in infectious disease pathology: Mechanisms, tissue damage, and clinical implications.

Pathology, research and practice·2026
Same author

Molecular modeling of highly selective CDK1 Inhibitors based on pyrazolo-pyrimidines using 3D-QSAR, docking, and molecular dynamics simulations.

PloS one·2026
Same author

Structure-based identification of potential antifungal agents against Aspergillus fumigatus through multiscale computational approaches.

Computational biology and chemistry·2026
Same author

Integrated density functional theory, molecular docking, and pharmacokinetic modeling of mukonal and its derivatives as inhibitors of the Plasmodium falciparum TFIIH complex (Tfb5 subunit).

Cellular and molecular biology (Noisy-le-Grand, France)·2026
Same author

5D and 6D bio-printed cellulose for neural tissue regeneration: advancement in next generation precision therapy.

Journal of biomaterials science. Polymer edition·2026

Related Experiment Video

Updated: Jun 21, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

BCL-2 in leukemia: Enhancing clinical utility.

Zia Ur Rehman1, Abida Khan2, Mohd Imran2

  • 1Health Research Centre, Jazan University, P.O. Box 114, Jazan 45142, Saudi Arabia.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|June 19, 2026
PubMed
Summary
This summary is machine-generated.

B-cell lymphoma 2 (BCL-2) protein is crucial for leukemia cell survival and drug resistance. While not a primary diagnostic marker, BCL-2 shows promise as a prognostic and predictive biomarker in leukemia treatment strategies.

Keywords:
ApoptosisBCL-2BiomarkerLaboratory assessmentLeukemiaPrognosisTreatment responseVenetoclax

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Experiment Videos

Last Updated: Jun 21, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • B-cell lymphoma 2 (BCL-2) is an anti-apoptotic protein vital for leukemic cell survival, apoptosis resistance, and drug resistance.
  • BCL-2 plays a central role in regulating apoptosis across various leukemia subtypes, making it clinically significant in hematopathology and laboratory medicine.

Purpose of the Study:

  • To review BCL-2's role as a prognostic, treatment-stratifying, and venetoclax-related predictive biomarker in leukemia.
  • To critically examine BCL-2's diagnostic utility and its association with leukemia biology, risk factors, and survival.
  • To address laboratory considerations for implementing BCL-2 assessment in clinical practice.

Main Methods:

  • Literature review summarizing data on BCL-2 expression and functional dependency in leukemia.
  • Exploration of BCL-2's utility in differentiating leukemic from non-malignant hematopoietic cells.
  • Discussion of laboratory methods including flow cytometry, immunohistochemistry, and transcript-based assessment.

Main Results:

  • BCL-2 is more strongly supported as a prognostic and treatment-stratifying marker than a diagnostic marker in leukemia.
  • BCL-2 functional dependency may be more informative than expression levels in venetoclax-based therapy.
  • Harmonized thresholds and validated workflows are needed for routine laboratory implementation.

Conclusions:

  • BCL-2 holds significant potential as an emerging biomarker in human leukemia within a laboratory medicine framework.
  • Further validation and standardization are required to integrate BCL-2 assessment into routine clinical practice.
  • BCL-2's role in predicting treatment response, particularly with venetoclax, warrants continued investigation.